Stoke Therapeutics (NASDAQ:STOK) Given Consensus Rating of “Buy” by Analysts

Shares of Stoke Therapeutics (NASDAQ:STOK) have been given a consensus rating of “Buy” by the ten ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $35.57.

A number of brokerages have recently commented on STOK. Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a research note on Monday, March 23rd. ValuEngine raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. Zacks Investment Research raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price on the stock in a research note on Thursday, May 28th. BidaskClub raised shares of Stoke Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 18th.

In other Stoke Therapeutics news, COO Huw M. Nash sold 2,107 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $27.18, for a total transaction of $57,268.26. Following the completion of the transaction, the chief operating officer now directly owns 2,107 shares of the company’s stock, valued at approximately $57,268.26. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Gene Liau sold 7,500 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $30.00, for a total transaction of $225,000.00. Following the transaction, the executive vice president now directly owns 21,000 shares of the company’s stock, valued at $630,000. The disclosure for this sale can be found here. Insiders have sold a total of 30,972 shares of company stock worth $846,656 in the last ninety days. 54.60% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in Stoke Therapeutics by 49.1% during the 1st quarter. BlackRock Inc. now owns 1,370,786 shares of the company’s stock worth $31,391,000 after acquiring an additional 451,363 shares in the last quarter. Lord Abbett & CO. LLC acquired a new position in Stoke Therapeutics during the 1st quarter worth $4,178,000. Bank of New York Mellon Corp grew its holdings in Stoke Therapeutics by 70.0% during the 1st quarter. Bank of New York Mellon Corp now owns 57,262 shares of the company’s stock worth $1,311,000 after acquiring an additional 23,581 shares in the last quarter. State Street Corp grew its holdings in Stoke Therapeutics by 73.4% during the 1st quarter. State Street Corp now owns 294,281 shares of the company’s stock worth $6,739,000 after acquiring an additional 124,537 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Stoke Therapeutics by 12.8% during the 1st quarter. Victory Capital Management Inc. now owns 202,563 shares of the company’s stock worth $4,639,000 after acquiring an additional 22,915 shares in the last quarter.

NASDAQ:STOK opened at $23.83 on Wednesday. The firm’s 50 day moving average is $25.39 and its two-hundred day moving average is $24.56. Stoke Therapeutics has a fifty-two week low of $15.82 and a fifty-two week high of $39.04. The company has a market cap of $765.23 million and a P/E ratio of -13.24.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Friday, May 15th. The company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. As a group, research analysts anticipate that Stoke Therapeutics will post -1.52 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Featured Article: What is a good rate of return for a mutual fund?

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.